Clinical Trial

Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Primary Objectives: To demonstrate that HT-4253 improves the amyloid risk profile by transitioning biomarker-positive APOE4 carriers from a positive, high risk APS2 score to a negative, low risk APS2 score. Secondary Objectives: * To assess the effects of HT-4253 on tau related blood biomarker progression over the study period. * To assess the effects of HT-4253 on amyloid related blood biomarker progression over the study period. * To assess the safety and tolerability of HT-4253 in the UAE population.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-08-06
notable Primary completion pushed: 2027-05-20 -> 2028-02 2026-08-06
minor Completion pushed: 2027-08-20 -> 2028-07 2026-08-06
Trial Details
NCT Number NCT07399171
Lead Sponsor Halia Therapeutics, Inc.
Conditions Alzheimers Disease
Enrollment 112 participants
Start Date 2026-05-12
Primary Completion 2028-02 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-05